SEC Form 4 · accession 0001209191-17-047556
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
K Peony Yu
Officer — Chief Medical Officer
Period of report
Aug 1, 2017
Accepted (ET)
Aug 3, 2017 · 8:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 1, 2017 | M | 10,000 | $14.575 | A | 226,507 | D | |
| Common StockF1,F2 | Aug 1, 2017 | S | 10,000 | $33.48 | D | 216,507 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $14.575 | Aug 1, 2017 | M | 10,000 | D | — | Mar 19, 2024 | Common Stock | 10,000 | 97,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices ranging from $33.45 to $34.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Fully vested.